NYSE - Delayed Quote • USD
Arcus Biosciences, Inc. (RCUS)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | -0.93 | -0.57 | -3.48 | -4.24 |
| Low Estimate | -1.21 | -1.26 | -4.92 | -5.99 |
| High Estimate | -0.42 | 2.21 | -1.28 | -2.41 |
| Year Ago EPS | -1.09 | -1.04 | -4.15 | -3.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 9 |
| Avg. Estimate | 35.56M | 29.7M | 191.65M | 166.61M |
| Low Estimate | 25M | 22.5M | 100M | 90M |
| High Estimate | 72.5M | 40M | 502.19M | 524.84M |
| Year Ago Sales | 25M | 30.3M | 117M | 191.65M |
| Sales Growth (year/est) | 42.20% | -2.00% | 63.80% | -13.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.16 | -1.1 | -1.13 | -1.02 |
| EPS Actual | -1.09 | -1.04 | -0.94 | -1.08 |
| Difference | 0.07 | 0.06 | 0.19 | -0.06 |
| Surprise % | 6.00% | 5.50% | 16.80% | -5.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.93 | -0.57 | -3.48 | -4.24 |
| 7 Days Ago | -0.93 | -0.57 | -3.48 | -4.24 |
| 30 Days Ago | -0.94 | -0.58 | -3.52 | -4.27 |
| 60 Days Ago | -0.93 | -0.61 | -3.47 | -4.03 |
| 90 Days Ago | -1.06 | -1.2 | -4.08 | -4.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RCUS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 14.70% | -- | -- | 2.60% |
| Next Qtr. | 45.20% | -- | -- | 13.40% |
| Current Year | 16.10% | -- | -- | 5.20% |
| Next Year | -21.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 3/25/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/22/2024 |
| Maintains | Wedbush: Outperform to Outperform | 1/30/2024 |
| Maintains | Mizuho: Buy to Buy | 1/30/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 1/17/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 11/13/2023 |
Related Tickers
NRIX Nurix Therapeutics, Inc.
12.36
-10.11%
ORIC ORIC Pharmaceuticals, Inc.
7.67
-5.07%
AKRO Akero Therapeutics, Inc.
18.93
-6.56%
ZLAB Zai Lab Limited
15.74
+0.51%
IGMS IGM Biosciences, Inc.
7.65
-3.89%
CYTK Cytokinetics, Incorporated
64.80
-3.02%
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.89%
KURA Kura Oncology, Inc.
19.00
+1.33%
RVMD Revolution Medicines, Inc.
35.33
-0.73%
BGNE BeiGene, Ltd.
148.56
+3.08%